Bispecific antibodies that bind to CD38 and CD3

Patent metadata

Field	Value
Publication number	US-9822186-B2
Application number	US-201514673695-A
Country	US
Kind code	B2
Filing date	Mar 30, 2015
Priority date	Mar 28, 2014
Publication date	Nov 21, 2017
Grant date	Nov 21, 2017

Abstract

The invention provides novel heterodimeric proteins including heterodimeric antibodies.

First claim

We claim:

1. A heterodimeric antibody comprising:
a) a first heavy chain comprising:
i) a first Fc domain variant;
ii) a single chain Fv region (scFv) that binds CD3; and

b) a second heavy chain comprising:
i) a second Fc domain variant; and
ii) a first variable heavy domain; and

c) a first light chain comprising a first variable light domain and a first constant light domain;
wherein said first variable heavy domain and said first variable light domain bind to CD38, and
wherein said second heavy chain and said first light chain are selected from the pairs consisting of H1(SEQ ID NO: 467) and L1 (SEQ ID NO: 469); H1 (SEQ ID NO: 473) and L1.24 (SEQ ID NO: 475); H1 (SEQ ID NO: 476) and L1.96 (SEQ ID NO: 478); H1.77 (SEQ ID NO: 479) and L1.96 (SEQ ID NO: 481); H1.77 (SEQ ID NO: 482) and L1.97(SEQ ID NO: 484); H1.72 (SEQ ID NO: 485) and L1.97(SEQ ID NO: 487); H1.71 (SEQ ID NO: 488) and L1.96 (SEQ ID NO: 490) and H1.77 (SEQ ID NO: 491) and L1.24 (SEQ ID NO: 493).

2. The heterodimeric antibody according to claim 1 wherein said second heavy chain and said first light chain are H1 (SEQ ID NO: 473) and L1.24 (SEQ ID NO: 475).

3. The heterodimeric antibody according to claim 1 wherein said scFv has a charged scFv linker.

4. The heterodimeric antibody according to claim 3 wherein charged scFv linker has a positive charge from 3 to 8 and is selected from the group consisting of SEQ ID NOs: 443 to 451.

5. The heterodimeric antibody according to claim 2 , wherein said scFv has a charged scFv linker.

6. The heterodimeric antibody according to claim 5 , wherein the charged scFv linker has a positive charge from 3 to 8 and is selected from the group consisting of SEQ ID NOs: 443 to 451.

7. The heterodimeric antibody according to claim 1 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.

8. The heterodimeric antibody according to claim 1 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.

9. The heterodimeric antibody according to claim 2 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.

10. The heterodimeric antibody according to claim 2 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.

11. The heterodimeric antibody according to claim 4 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.

12. The heterodimeric antibody according to claim 4 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.

13. The heterodimeric antibody according to claim 5 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.

14. The heterodimeric antibody according to claim 5 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.

15. The heterodimeric antibody according to claim 6 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.

16. The heterodimeric antibody according to claim 6 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.

Assignees

• Xencor Inc

Inventors

• Bernett Matthew
• Chu Seung
• Moore Gregory
• Desjarlais John

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• C07K16/30

  from tumour cells · CPC title

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title